News Category
Onco-Innovations reports significant progress in developing ONC010, a PNKP inhibitor for cancer therapy, including high-purity API production and plan...
VERAXA Biotech AG (NASDAQ: VRXA) has appointed Raju Willener as CFO to lead its capital strategy and support the development of its proprietary BiTAC(...
BioVersys, a clinical-stage biopharmaceutical company developing novel antibacterials for multi-drug resistant infections, will present a corporate ov...
OS Therapies is set to engage with investors at the Moody Capital conference while approaching critical regulatory decisions and data readouts for its...
A preclinical study suggests that administering immunotherapy before tumor removal surgery could improve treatment outcomes for glioblastoma patients,...
Tonix Pharmaceuticals will showcase its CNS and immunology pipeline at the Cantor 2026 Global Healthcare Conference, highlighting recent approvals and...
NurExone Biologic will showcase its exosome-based therapeutic platform and U.S. initiatives at a New York conference, highlighting progress toward cli...
CNS Pharmaceuticals' Chief Business Officer discussed the company's focused pipeline strategy and deal-making criteria, signaling a disciplined approa...
Hong Kong launched SEAM@InnoHK, its third research cluster, focusing on sustainability and advanced manufacturing, to strengthen its position as a glo...
Quantum BioPharma's Lucid-MS candidate for progressive multiple sclerosis earns a 'Buy' rating and $8 price target from Rodman & Renshaw, highlighting...
NanoViricides is progressing its measles treatment NV-387 to Phase II trials, leveraging FDA designations, as measles cases surge globally.
TransCode Therapeutics announced preclinical results showing its lead candidate TTX-MC138 improves survival in a breast cancer bone metastasis model, ...
Oragenics reports progress in its Phase IIa trial for a concussion treatment and responds to NYSE American listing deficiency, highlighting regulatory...
Creative Biolabs updates its in vivo CAR-T development portfolio with viral and non-viral approaches, offering researchers new options to overcome ex ...
Lonza's creation of a Chief Commercial Officer role and appointment of Samanta Cimitan underscores its commitment to a unified customer experience and...
Heidelberg Pharma and Huadong Medicine have received NMPA approval for a Phase Ib/II trial of HDP-101 in combination therapies for relapsed/refractory...
A new peer-reviewed study published in Critical Care Medicine shows that VolitionRx's Nu.Q NETs H3.1 biomarker independently predicts 28-day mortality...
Monod Bio's licensing agreement with SignalChem Biotech integrates AI-designed LuxSit luciferase and NovoBodies into custom assay services, expanding ...
GeoVax Labs secures immediate funding through a warrant inducement transaction, boosting its cash position for advancing its mpox vaccine and oncology...
Lakewood-Amedex Biotherapeutics, a clinical-stage biotech developing the novel Bisphosphocin class of antimicrobials, becomes a B2i Digital Featured C...
Citius Pharmaceuticals is transitioning to a commercial-stage biopharma with FDA-approved LYMPHIR generating revenue, while advancing late-stage candi...
Annovis Bio announced a corporate update webinar for September 2, discussing its Phase 3 Alzheimer's trial, open-label studies, and regulatory milesto...
A new study suggests a personalized mRNA vaccine can prevent melanoma recurrence for years, offering hope for cancer treatment.
Creative Biolabs announces a webinar featuring Dr. Greg M. Delgoffe to discuss modeling T cell dysfunction in the tumor microenvironment, highlighting...
Synthesis Peptides now provides third-party Certificates of Analysis for all 40-plus research peptides, enhancing transparency and reliability for sci...
A new T cell therapy could transform treatment for recurrent glioblastoma, a disease with few effective options, offering new hope for patients.
VERAXA Biotech and Secarna's early in vitro results show their AOC candidate is more potent than unconjugated oligonucleotides, supporting the approac...
VERAXA Biotech has moved its VXA-222 bispecific antibody-drug conjugate program into the next development stage after completing the initial OmniAb co...
Scinai Immunotherapeutics reported increased revenue and a net profit for the first half of 2026, while advancing an expanded clinical manufacturing p...
A new composite scoring system, the Seven Up score, may prevent overtreatment of early rejection in liver transplant recipients, as research shows mos...
VERAXA Biotech received favorable Scientific Advice from Germany's Paul-Ehrlich-Institute for its lead BiTAC-TCE cancer therapy, potentially reducing ...
VERAXA Biotech's proprietary BiTAC platform aims to improve cancer therapy precision, with lead programs advancing toward regulatory activities and a ...
Onco-Innovations has entered a non-binding LOI with Ifowonco Informatics to potentially acquire an exclusive option on a small-molecule LAG-3 inhibito...
Creative Biolabs has expanded its complement assay services to help researchers evaluate complement-targeting therapeutics, addressing the growing nee...
Quantum BioPharma is advancing a novel MS treatment focusing on myelin protection, potentially addressing disease progression that current therapies m...
Silo Pharma's lead asset SPC-15, an intranasal treatment for PTSD, has received a Notice of Allowance from the Canadian Intellectual Property Office, ...
Quantum BioPharma's FDA-cleared phase 2 trial of Lucid-MS highlights a shift in MS treatment toward protecting the nervous system, addressing an unmet...
Regentis Biomaterials received a Japanese Notice of Allowance for its solvent-free manufacturing process and liquid formulation for GelrinC, strengthe...
VERAXA Biotech's collaboration with Ardigen aims to use AI to identify optimal dual-target combinations for cancer therapies, potentially reducing dev...
VERAXA Biotech's collaboration with AI-focused Ardigen aims to use artificial intelligence to identify optimal dual-target combinations for cancer the...
Nanox Imaging's subsidiary has secured an exclusive UK distribution deal for its AI-powered bone health software, following a NICE recommendation for ...
Helix BioPharma Corp. has appointed Dr. Markus Loeffler as Chief Medical Officer to lead its clinical development programs, including the upcoming Pha...
Quantum BioPharma reported reduced Q2 expenses and received FDA clearance to advance Lucid-MS into a Phase 2 trial for progressive multiple sclerosis,...
Regentis Biomaterials is progressing its cartilage repair product GelrinC through a pivotal U.S. clinical trial while simultaneously scaling European ...
Helix BioPharma reshapes its board with the resignation of Janusz Grabski and appointment of CEO Thomas Mehrling, aiming to align governance with clin...
Onco-Innovations is progressing its biomarker-driven cancer therapy ONC010 through key manufacturing and metabolic studies, positioning it for first-i...
Researchers at the University of Manchester have discovered that a subset of immune cells, often overlooked, is essential for mobilizing the immune sy...
Quantum BioPharma reported a 53% reduction in operating expenses and received FDA approval to begin Phase 2 trials for its multiple sclerosis drug Luc...
